All In Biotech

Drug Trial Radar · NCT07371468

A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)

A Phase 1, Open-label, Dose-escalation Study (ELEVATE-1) to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of a CD19/CD20 T-cell Engager in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)

Last checked: Nov 20, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

44

Planned (sponsor's estimate)

Start

Feb 10, 2026

Primary completion

Mar 15, 2028

Study completion Mar 15, 2028

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jan 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 2-part study of GSK5926371 in participants with autoimmune rheumatic diseases (ARD). In part 1, participants will receive different doses of GSK5926371 to find a suitable priming dose. In part 2, participants will receive GSK5926371 at doses based on data from part 1. The study is aimed at testing if GSK5926371 is safe, well-tolerated, how the body processes the study drug, how it works in the body, and whether it triggers any immune responses.

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • GSK5926371Biological

    GSK5926371 will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 and Part 2: Number of Participants with Adverse Events (AEs) and Serious AEs (SAEs)Time frame: Up to 196 days

Locations

19 sites in 9 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Buenos Aires, Argentina · Recruiting

  • GSK Investigational Site

    San Miguel de Tucumán, Argentina · Recruiting

  • GSK Investigational Site

    Campinas, São Paulo, Brazil · Recruiting

  • GSK Investigational Site

    São Paulo, São Paulo, Brazil · Recruiting

  • GSK Investigational Site

    Bordeaux, France · Recruiting

  • GSK Investigational Site

    Toulouse, France · Recruiting

  • GSK Investigational Site

    Cona, Ferrara, Italy · Recruiting

  • GSK Investigational Site

    Fukuoka, Japan · Recruiting

  • GSK Investigational Site

    Hiroshima, Japan · Recruiting

  • GSK Investigational Site

    Hokkaido, Japan · Recruiting

  • GSK Investigational Site

    Panama City, Panama · Recruiting

  • GSK Investigational Site

    Panama City, Panama · Recruiting

  • GSK Investigational Site

    Panama City, Panama · Recruiting

  • GSK Investigational Site

    Poznan, Poland · Recruiting

  • GSK Investigational Site

    Warsaw, Poland · Recruiting

  • GSK Investigational Site

    Barcelona, Spain · Recruiting

  • GSK Investigational Site

    Madrid, Spain · Recruiting

  • GSK Investigational Site

    Madrid, Spain · Recruiting

  • GSK Investigational Site

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.